Handelsavisen
prelaunch
Companies ›Healthcare ›AAPG.O
AA
AAPG.O — NASDAQ Biotechnology

Aapg.O

$16,80
Open in Charts → Attach watcher ⌖
— —
USD
Set alert
Last 30 days
1D5D1M3M6MYTD1Y5YMax
Live price chart loads from the market-data widget.
Mcap
6,3B USD
P/E
—
EV / Rev
—
Div yield
—
Op margin
—
ROE
—
Net margin
—
Debt / equity
—
Beta
—
52w range
—
Volume
—
Day range
—
Prev close
$16,81
Open
—
Next earnings
—
Ex-dividend
—
TR 1Y
—
About

Ascentage Pharma Group operates in the pharmaceuticals industry within the healthcare sector, though specific revenue-generating activities and product lines are not detailed in the available data.

Business. Ascentage Pharma Group operates in the pharmaceuticals industry within the healthcare sector, though specific revenue-generating activities and product lines are not detailed in the available data.

Classification85 %
SectorHealth Care
Industry groupBiotechnology
Generated · model-assisted
Sell-side consensus
BUY8 analysts
8 buy0 hold0 sell
Avg 12m price target48,14

Analyst recommendations

8 analysts · consensus Buy
Buy8
Hold0
Sell0
12-month price target
48,14
Consensus of sell-side coverage.
Upcoming events
— missing data
See all catalysts →

At a glance

Score
—
not yet scored
Valuation
—
valuation pending
Analysts→
Buy
8 analysts · indicative
Ownership→
Morgan Stanley Smith Barney LLC
largest disclosed fund holder
Profitability
—
not yet wired
Quality
—
not yet scored

What drives this business

The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.

— missing data

News & coverage

0
  • No recent newsroom coverage mentioning AAPG.

    • Sector rotation

    Sector1D1Mvs mkt
    Materials+2,3 %+6,6 %+1,7 %
    Communication Services+2,2 %−5,5 %+1,6 %
    Energy+0,6 %+3,3 %+0,0 %
    Health Care · THIS SECTOR+0,6 %−0,8 %+0,0 %
    Information Technology+0,6 %+6,7 %+0,0 %
    Consumer Discretionary+0,4 %+7,6 %−0,2 %
    Financials−0,3 %−2,8 %−0,9 %
    Consumer Staples−0,4 %+2,5 %−1,0 %
    Real Estate−0,7 %+10,9 %−1,3 %
    Industrials−1,9 %−3,1 %−2,5 %
    Utilities−1,9 %+28,2 %−2,5 %

    Developing storylines

    No tracked sagas currently linked to AAPG.O. Browse all sagas →

    Analysis

    AI analysis
    Generated · analysis pipeline · tier hybrid · as of 2026-08-04 ↑ At a glance

    Opportunity

    — missing data

    Upcoming catalysts

    Scheduled public events. Informational only — not investment advice.

    • Macro
    • Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
    • Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
    • Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
    • Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
    • Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
    • Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
    • Macro & political
    • ElectionSE Swedish Election2026-09-14 · SE
    • ElectionUS U.S. Midterms2026-11-03 · US
    • ElectionFR French Legislative2027-06-01 · FR

    Pre-earnings brief

    — missing data

    Signals & dispatch

    peak dispatch · —

    Composite-score breakdown

    Synthesis

    Business

    Ascentage Pharma Group operates in the pharmaceuticals industry within the healthcare sector, though specific revenue-generating activities and product lines are not detailed in the available data.

    Classification85 %
    SectorHealth Care
    Industry groupBiotechnology
    AI synthesis
    GENERATED
    — missing data
    Key takeaways
    • Liquidity and capital structure analysis is constrained by missing balance-sheet data, preventing assessment of debt levels or cash positions.
    • Dilution risk is low, as basic and diluted share counts are identical at 373.3 million shares.
    • Analyst sentiment is strongly positive, with a mean recommendation of 1.75 and a mean price target of $48.14, implying significant upside from the current $16.80 price.
    • No profitability, growth, or segment data is available to support fundamental valuation or operational analysis.
    • Classification confidence is moderate at 0.66, with the company identified in the Pharmaceuticals industry.

    Bull / Bear case

    analysis pipeline
    — missing data

    In focus — financials by report

    Valuation

    Market price
    $16,80
    Market cap
    $6.27B
    Enterprise valueⓘ
    —
    P/Eⓘ
    —
    Non-GAAP P/Eⓘ
    —
    EV / Revenueⓘ
    —
    EV / Op incomeⓘ
    —
    EV / OCFⓘ
    —
    P / Bⓘ
    —
    P / Tangible bookⓘ
    —
    Tangible book
    —
    Net cashⓘ
    —
    Current ratioⓘ
    —
    Debt / equityⓘ
    —
    ROAⓘ
    —
    ROEⓘ
    —
    Cash conversionⓘ
    —
    CapEx / revenueⓘ
    —
    SBC / revenueⓘ
    —
    Dilution ratioⓘ
    0.0%

    Revenue by segment

    Market share

    — missing data

    Business relationships

    Business relationships2 disclosed relationships · 1 type · extracted from filings & disclosures

    Supply chain

    Vendors → AAPG ↔ Partners → Customers · click any node to drill
    VENDORSPARTNERSCUSTOMERSAAPGAAPGAapg.O2 entitiesInnovent Biologics IncPharmaceuticalsHKTakeda Pharmaceutical PharmaceuticalsJP
    2 mentions in 10-K0 from corporate websites0 from news dispatches
    Updated 2026-06-24

    Peer comparison

    — missing data

    Market position

    Stress test

    — missing data

    Predictor forecast

    Options

    — missing data

    Short squeeze

    — missing data

    Earnings-call key lines

    — missing data

    Consensus distribution

    sell-side coverage
    Recommendation distribution9 analysts
    Strong buy2
    Buy7
    Hold0
    Sell0
    Strong sell0
    12-month price target$47,75 · Median $48,00
    Low $40,00High $55,00
    Operating income · consensus-169,1M
    EPS surprise
    −192,8 %
    reported vs consensus · miss
    Revenue surprise
    −31,4 %
    reported vs consensus · miss

    Estimate revisions

    consensus EPS · 26-week trend
    — missing data

    Sell-side observations

    Low$40,00
    Mean$48,14
    Median$48,00
    High$55,00
    Spot$16,80
    +186.6 %implied to mean12-month sell-side price targets · ▲ spot

    Themes

    — missing data

    ESG

    — missing data

    Risk factors

    Dilution riskLow
    Liquidity riskUnknown

    Benchmarks vs cohort

    No cohort benchmark data available for this issuer yet.

    Corporate actions / M&A

    — missing data

    FX exposure

    — missing data

    Comparable transactions

    — missing data

    Derivatives & instruments

    Derivative transactions

    Net acquired 2 484 794 sh4 exercises · 17 grants3 insiders
    • Zhai YifanChief Medical Officer · Restricted stock units → Ordinary SharesDisposed 95 575exercise · 2026-05-21
    • Zhai YifanChief Medical Officer · Restricted stock units → Ordinary SharesDisposed 92 746exercise · 2026-05-21
    • Yang DajunDirector, Chairman and CEO · Restricted stock units → Ordinary SharesDisposed 92 746exercise · 2026-05-21
    • Yang DajunDirector, Chairman and CEO · Restricted stock units → Ordinary SharesDisposed 95 575exercise · 2026-05-21
    • Zhai YifanChief Medical Officer · Restricted stock units → Ordinary SharesAcquired 103 365grant · 2026-05-20
    • Zhai YifanChief Medical Officer · Options → Ordinary SharesAcquired 214 988 @ $6,58grant · 2026-05-20
    • Zhai YifanChief Medical Officer · Options → Ordinary SharesAcquired 103 364 @ $8,12grant · 2026-05-20
    • Zhai YifanChief Medical Officer · Restricted stock units → Ordinary SharesAcquired 92 746grant · 2026-05-20
    • Yang DajunDirector, Chairman and CEO · Restricted stock units → Ordinary SharesAcquired 214 999grant · 2026-05-20
    • Yang DajunDirector, Chairman and CEO · Options → Ordinary SharesAcquired 214 988 @ $6,58grant · 2026-05-20
    • Zhai YifanChief Medical Officer · Restricted stock units → Ordinary SharesAcquired 214 999grant · 2026-05-20
    • Yang DajunDirector, Chairman and CEO · Restricted stock units → Ordinary SharesAcquired 298 195grant · 2026-05-20
    • Yang DajunDirector, Chairman and CEO · Options → Ordinary SharesAcquired 103 364 @ $8,12grant · 2026-05-20
    • Yang DajunDirector, Chairman and CEO · Restricted stock units → Ordinary SharesAcquired 95 575grant · 2026-05-20
    • Zhai YifanChief Medical Officer · Options → Ordinary SharesAcquired 298 194 @ $6,58grant · 2026-05-20
    • Yang DajunDirector, Chairman and CEO · Options → Ordinary SharesAcquired 298 194 @ $6,58grant · 2026-05-20
    • Zhai YifanChief Medical Officer · Restricted stock units → Ordinary SharesAcquired 95 575grant · 2026-05-20
    • Yang DajunDirector, Chairman and CEO · Restricted stock units → Ordinary SharesAcquired 103 365grant · 2026-05-20
    • Yang DajunDirector, Chairman and CEO · Restricted stock units → Ordinary SharesAcquired 92 746grant · 2026-05-20
    • Zhai YifanChief Medical Officer · Restricted stock units → Ordinary SharesAcquired 298 195grant · 2026-05-20
    • Misra VeetChief Financial Officer · Restricted stock units → Restricted stock unitsAcquired 18 584grant · 2026-04-20

    Actions

    Ask Handelsavisen

    — missing data
    Data sources
    • Reference data
    • Market data cache
    • Issuer disclosures
    • Public news
    • Earnings transcripts
    • Consensus estimates
    • ESG data
    How metrics are computed
    • Market Price
      input from market-data provider (delayed close or quote-shim mid)
    • Dilution Ratio
      (shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
    • Market Cap
      market_price * shares_outstanding_diluted
    Source documents
    • ASCENTAGE PHARMA GROUP INTERNATIONAL Market data — financials · 2026-08-04
    • reconciler_enqueue (reconciler) on AAPG.O · 2026-08-04
    • Ascentage Pharma Group International Market data — analyst estimates · 2026-08-04
    • AAPG.O HA canonical relationships · 2026-08-04

    Ownership & reference

    Top holders

    • Morgan Stanley Smith Barney LLCInvestment Managers · as of 2026-03-310,00 %$0M
    • UBS Financial Services, Inc.Investment Managers · as of 2026-03-310,00 %$0M

    Insider activity

    Mixed / flat0 buys · 0 sellsnet $02 insiders · last 365d
    • Zhai YifanChief Medical Officer · Ordinary SharesOther 95 575 · 2026-05-21
    • Zhai YifanChief Medical Officer · Ordinary SharesOther 92 746 · 2026-05-21
    • Yang DajunDirector, Chairman and CEO · Ordinary SharesOther 92 746 · 2026-05-21
    • Yang DajunDirector, Chairman and CEO · Ordinary SharesOther 95 575 · 2026-05-21

    Short positioning

    20.2Kshares short-87.2% vs prior
    2.22days to cover
    70.9%short of daily vol
    148fails-to-deliver
    as of 2026-07-15 · short-interest report (free)

    Geographic breakdown

    — missing data
    Listings · one canonical issuer all listings resolve to the canonical
    AAPG.OCanonical
    NASDAQ · USD

    Intel & risk

    peak dispatch · —
    OSINT findings
    Dilution riskLow
    Liquidity riskUnknown
    Relationship graph
    AAPG1801.HK4502.TBiotechnology
    This companySectorPartners

    Evidence & claims

    From filings & derived data
    — missing data

    The Thread

    Everything we know, in order
    — missing data
    Sources filings · IR · transcripts · market data · tier hybrid · as of 2026-08-04 Reference data · Issuer disclosures · Public news · Earnings transcripts · Consensus estimates · ESG data Premium coverage